©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 28, 2026; 32(8): 115291
Published online Feb 28, 2026. doi: 10.3748/wjg.v32.i8.115291
Published online Feb 28, 2026. doi: 10.3748/wjg.v32.i8.115291
Cost-effectiveness of different strategies with biologics for the treatment of moderate to severe Crohn’s disease in China
Yao Wu, Li-Bo Tao, Chang Liu, Fang-Xu Wang, Yi Yan, Shuang Sun, Center for Health Policy and Technology Evaluation, Peking University Health Science Center, Beijing 100191, China
Li-Bo Tao, Department of Health Policy and Management, School of Public Health, Peking University, Beijing 100191, China
Author contributions: Wu Y and Tao LB formulated the research idea; Wu Y, Tao LB, Yan Y, and Sun S developed the manuscript; Wu Y, Liu C, and Wang FX conducted the data analysis; all authors have critically reviewed the manuscript and approved this manuscript submission.
Conflict-of-interest statement: No conflicts of interest to declare.
STROBE statement: The authors have read the STROBE Statement – checklist of items, and the manuscript was prepared and revised according to the STROBE Statement – checklist of items.
Data sharing statement: All data supporting the findings of this study are included within the article and Supplementary material. No additional data are available.
Corresponding author: Li-Bo Tao, PhD, Senior Researcher, Center for Health Policy and Technology Evaluation, Peking University Health Science Center, No. 38 Xueyuan Road, Haidian District, Beijing 100191, China. taolibo@hsc.pku.edu.cn
Received: October 15, 2025
Revised: December 23, 2025
Accepted: February 3, 2026
Published online: February 28, 2026
Processing time: 121 Days and 5.2 Hours
Revised: December 23, 2025
Accepted: February 3, 2026
Published online: February 28, 2026
Processing time: 121 Days and 5.2 Hours
Core Tip
Core Tip: Using a Markov model, this study evaluated the cost-effectiveness of 17 sequential biologic strategies for moderate-to-severe Crohn’s disease in China. Under a willingness-to-pay threshold of one time the 2024 GDP per capita, the findings suggest that while additional lines of biologic therapy improve health outcomes, they concurrently increase costs. The sequence initiating with adalimumab and followed by ustekinumab emerged as the most cost-effective option, yielding the highest net monetary benefit and a favorable incremental cost-effectiveness ratio for both biologic-naïve and biologic-exposed patients.